INBRX-120

N/A

Report date: 2023/12/28 16:35:43

Base Information

Drug NameINBRX-120

Drug Alias NameCD8α-targeted Cisleukin™ molecule (Inhibrx)INBRX-120

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCD8A modulatorsInterleukin-2 replacements

TargetsT-cell surface glycoprotein CD8 alpha chainInterleukin-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesInhibrx Inc

China Registration ClassN/A

Develop Information

Active CompaniesInhibrx Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A